Moreover, we found that combining the clinical characteristics of DLBCL by TRIB3 expression could better predict the prognosis of DLBCL patients, suggesting TRIB3 might serve as a potential therapeutic target and prognostic factor in DLBCL. The gene discussed is TRIB3; the disease is diffuse large B-cell lymphoma.